The NSW Government is investing $9 million over the next five years on clinical trials that will explore the use of cannabis and cannabis products in providing relief from a range of debilitating or terminal illnesses.
Three clinical trials were announced in December 2014 to explore the use of cannabis and cannabis products in providing relief for:
- Children with severe, drug-resistant epilepsy, through a partnership with the Sydney Children’s Hospitals Network
- Adults with terminal illness, focusing on improving quality of life, and symptoms such as pain, nausea and vomiting
- Adults with chemotherapy-induced nausea and vomiting, where standard treatment is ineffective.
How can I become a participant in these clinical trials?
Once the scope of each trial is finalised, further information on eligibility will be available.
What type of cannabis products will be used in these clinical trials?
Cannabis is a complex plant that contains a range of different chemicals, called cannabinoids. The concentration of cannabinoids varies from strain to strain of plant, and depends on the type of growing and harvesting conditions.
To ensure the clinical trials produce reliable results, they must use a standardised product that meets the strict standards of production as well as the Therapeutic Goods Administration Clinical Trials standards. Suitable products will be assessed as part of the application process to conduct the clinical trials.
Progress on establishing the clinical trials
Details of a clinical trial for adults with terminal illness and a clinical trial for children with severe epilepsy have now been announced.
For adults with chemotherapy-induced nausea and vomiting, the NSW Government is working with the research community to ensure high quality trials are developed. More information will be made available as these discussions progress.